Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 7, 2012
Woodcliff Lake, NJ, March 6, 2012 - Eisai Inc. today announced that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New...
-
Mar 5, 2012
Woodcliff Lake, NJ, March 5, 2012 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA)...
-
Feb 10, 2012
On February 9, 2012, the U.S. Food and Drug Administration's (FDA's) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 3 with one abstention that the data in the company's...
-
Feb 1, 2012
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, February 1, 2012 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified...
-
Jan 30, 2012Two Innovative Programs Will Help Eliminate Lymphatic Filariasis By 2020
Tokyo, Japan, January 30, 2012 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"), as one of the thirteen major research and development-based pharmaceutical...